Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis announces new president of NIBR

Novartis announces new president of NIBR

25th September 2015

Novartis has appointed Dr James Bradner as president of the Novartis Institutes for BioMedical Research (NIBR) and a member of its executive committee.

The physician-scientist from Dana-Farber Cancer Institute and Harvard Medical School will take up his new position on March 1st 2016, succeeding Dr Mark Fishman, who is retiring from the company.

Dr. Bradner is on the faculty of Harvard Medical School in the department of medical oncology at the Dana-Farber Cancer Institute. He has co-authored more than 130 scientific publications and 30 US patent applications.

Joseph Jimenez, chief executive officer of Novartis, said: "His experience and perspectives make him a great fit to further develop our internal research capabilities, as well as expand our external collaboration efforts with biotech companies and academic institutions."

Following a distinguished 13-year career at Novartis, Dr Fishman has reached his contractual retirement age and will step down from leading the company's drug discovery and early clinical development efforts.

This comes after Novartis Access, a portfolio of medicines to treat chronic diseases in low-income countries.ADNFCR-8000103-ID-801801444-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.